BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ellipses Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ellipses Pharma's drugs run\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05265091-2472@assetmemo.bio
DTSTAMP:20261121T005322Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05265091)
DESCRIPTION:Lunbotinib\, phase 1/2.\nStudy: A Study of KL590586 in Patients
  With Advanced Solid Tumors\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lunbotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05265091
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05443126-2472@assetmemo.bio
DTSTAMP:20261121T005322Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05443126)
DESCRIPTION:Lunbotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Maligna
 ncies\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lunbotinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05443126
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04581512-2903@assetmemo.bio
DTSTAMP:20261121T005322Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mobinitinib: Phase 1/2 readout est. (NCT04581512)
DESCRIPTION:Mobinitinib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Study
  to Evaluate the Safety and Tolerability of EP0042\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mobinitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04581512
URL:https://assetmemo.bio/drug/mobinitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05573126-9119@assetmemo.bio
DTSTAMP:20261121T005322Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Vosilasarm: Phase 1/2 readout est. (NCT05573126)
DESCRIPTION:Vosilasarm\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination
  in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer\nEst
 imated primary completion: February 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/vosilasarm#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05573126
URL:https://assetmemo.bio/drug/vosilasarm#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
